drugset / Trial / NCT04168138

D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

NCT04168138

Unknown 20 enrolled Huihan Wang
NaSingle-groupOpen-labelTreatment

Summary

With the aging of society, the incidence of elderly leukemia in China has been increasing year by year. The elderly patients with Acute Leukemia have poor basal state, and there are many important organ diseases such as heart, liver and kidney. The incidence of infection and hemorrhage is high in elderly patients after chemotherapy. These characteristics make the treatment of elderly leukemia difficult. So we propose a new treatment plan by using the therapy that rhTPO may promote the leukemia cells into the division cycle.We use the synergistic effect of G-CSF and rhTPO to promote leukemia cells into the division cycle, thereby the cells can be killed by cytotoxic drugs. At the same time, G-CSF and rhTPO are used to promote the growth of granulocytes and platelets, therefore the side effects of treatment of elderly leukemia can be alleviated. We provide a safe and effective chemotherapy for elderly leukemia patients, so that more elderly patients receive chemotherapy,which has important practical significance.

Timeline

Start
2019-11-01
Primary completion
2021-12-30
Completion
2024-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Aclarubicin Small molecule 10 mg
Subject Cytarabine Small molecule 15 mg
Subject Decitabine Small molecule 15 mg/m2
Subject Granulocyte colony-stimulating factor Protein / enzyme biologic 300 ug
Subject recombinant human thrombopoietin Protein / enzyme biologic 15000 iu